Created in partnership with Parkinson's UK, the Critical Path for Parkinson's Consortium (CPP) was launched in 2015. It is a global collaboration that facilitates collaboration among scientists from the bio-pharmaceutical industry, academic institutions, government agencies, and patient-advocacy associations. It fosters consensus and data-driven research to increase efficiency, safety, and speed in developing new therapies.
The Oxford Parkinson's Disease Centre is jointly led by Professor Michele Hu and Professor Richard Wade-Martins.